IL150080A0 - Methods of detection of amyloidogenic proteins - Google Patents
Methods of detection of amyloidogenic proteinsInfo
- Publication number
- IL150080A0 IL150080A0 IL15008000A IL15008000A IL150080A0 IL 150080 A0 IL150080 A0 IL 150080A0 IL 15008000 A IL15008000 A IL 15008000A IL 15008000 A IL15008000 A IL 15008000A IL 150080 A0 IL150080 A0 IL 150080A0
- Authority
- IL
- Israel
- Prior art keywords
- aggregation
- assay
- amyloid
- peptide
- amyloid peptide
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 102000009091 Amyloidogenic Proteins Human genes 0.000 title 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 title 1
- 238000001514 detection method Methods 0.000 title 1
- 230000002776 aggregation Effects 0.000 abstract 4
- 238000004220 aggregation Methods 0.000 abstract 4
- 238000003556 assay Methods 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 2
- 238000004847 absorption spectroscopy Methods 0.000 abstract 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 abstract 1
- 238000002983 circular dichroism Methods 0.000 abstract 1
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 abstract 1
- 230000035557 fibrillogenesis Effects 0.000 abstract 1
- 238000001506 fluorescence spectroscopy Methods 0.000 abstract 1
- 238000010874 in vitro model Methods 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 239000000523 sample Substances 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/474,970 US6399314B1 (en) | 1999-12-29 | 1999-12-29 | Methods of detection of amyloidogenic proteins |
| PCT/US2000/032693 WO2001050134A2 (en) | 1999-12-29 | 2000-12-01 | Methods of detection of amyloidogenic proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL150080A0 true IL150080A0 (en) | 2002-12-01 |
Family
ID=23885720
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15008000A IL150080A0 (en) | 1999-12-29 | 2000-12-01 | Methods of detection of amyloidogenic proteins |
| IL150080A IL150080A (en) | 1999-12-29 | 2002-06-06 | Methods for detecting amyloidogenic proteins |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL150080A IL150080A (en) | 1999-12-29 | 2002-06-06 | Methods for detecting amyloidogenic proteins |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6399314B1 (de) |
| EP (1) | EP1242822B1 (de) |
| JP (1) | JP2003519383A (de) |
| KR (1) | KR20020070470A (de) |
| CN (1) | CN1211661C (de) |
| AT (1) | ATE399323T1 (de) |
| AU (1) | AU774377B2 (de) |
| BR (1) | BR0016883A (de) |
| CA (1) | CA2395789C (de) |
| DE (1) | DE60039310D1 (de) |
| DK (1) | DK1242822T3 (de) |
| EA (1) | EA005582B1 (de) |
| ES (1) | ES2309003T3 (de) |
| HK (1) | HK1046550B (de) |
| IL (2) | IL150080A0 (de) |
| MX (1) | MXPA02006362A (de) |
| NO (1) | NO20023163L (de) |
| NZ (1) | NZ519612A (de) |
| PL (1) | PL356813A1 (de) |
| PT (1) | PT1242822E (de) |
| WO (1) | WO2001050134A2 (de) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
| US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| US7179892B2 (en) * | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US7588766B1 (en) | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
| US20030147882A1 (en) * | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
| DE19923811C1 (de) * | 1999-05-20 | 2000-12-07 | Robert Koch Inst | Verfahren zur Diagnose TSE-induzierter Veränderungen in Geweben mittels Infrarotspektroskopie |
| US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
| US6689753B1 (en) * | 1999-11-05 | 2004-02-10 | Axonyx, Inc. | β sheet breaker peptide analogs that inhibit β pleated sheet formation in amyloid β-peptide |
| EP1322959A1 (de) | 2000-08-21 | 2003-07-02 | The General Hospital Corporation | Verfahren zur diagnose eines neurodegenerativen zustandes |
| US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
| TWI255272B (en) * | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| WO2003018068A1 (en) * | 2001-04-27 | 2003-03-06 | The General Hospital Corporation | Ocular diagnosis of alzheimer's disease |
| US20050026165A1 (en) * | 2001-05-31 | 2005-02-03 | Cindy Orser | Detection of conformationally altered proteins and prions |
| EP1395833B1 (de) * | 2001-05-31 | 2013-02-27 | Adlyfe, Inc. | Verfahren zum erkennen von inkorrekt gefalteten proteinen |
| EP1455826A2 (de) * | 2001-12-21 | 2004-09-15 | Ilex Oncology, Inc. | Kombination die anti-cd52 antikörper und sonstige therapeutische agenzien enthält zur behandlung von multipler sklerose |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| US20070003552A1 (en) * | 2002-07-09 | 2007-01-04 | Gebbink Martijn F B | Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation |
| EP1380290A1 (de) * | 2002-07-09 | 2004-01-14 | Universitair Medisch Centrum Utrecht | Cross-Beta-Strukturweg und seine therapeutische Relevanz |
| PE20050627A1 (es) | 2003-05-30 | 2005-08-10 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido beta amiloideo |
| US20050048539A1 (en) * | 2003-06-13 | 2005-03-03 | The General Hospital Corporation | Methods to monitor molecule conformation and molecule/molecule proximity |
| SE0401219D0 (sv) * | 2004-05-10 | 2004-05-10 | Biochromix Ab | Metoder för detektera konformationsförändringar eller aggregering hos proteiner med hjälp av konjugerade polyelektrolyter |
| US20060057671A1 (en) * | 2004-09-10 | 2006-03-16 | Orser Cindy S | Immobilized probes and methods of detecting conformationally altered prion proteins |
| WO2006066089A1 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | Humanized amyloid beta antibodies for use in improving cognition |
| TW200636066A (en) * | 2004-12-15 | 2006-10-16 | Elan Pharm Inc | Humanized antibodies that recognize beta amyloid peptide |
| EP1838349A1 (de) * | 2004-12-15 | 2007-10-03 | Neuralab, Ltd. | Amyloid-beta-antikörper zur verbesserung der kognition |
| JP4568840B2 (ja) * | 2004-12-28 | 2010-10-27 | 国立大学法人金沢大学 | アルツハイマー病の検査方法 |
| WO2006069697A1 (en) * | 2004-12-30 | 2006-07-06 | F. Hoffmann-La Roche Ag | Colorimetrically assessing peptide characteristics |
| EP1853915B1 (de) * | 2005-02-15 | 2011-10-12 | Adlyfe, Inc. | Verfahren zum nachweis falsch gefalteter proteine und prionen |
| US20090202980A1 (en) * | 2005-03-21 | 2009-08-13 | Crossbeta Biosciences B.V. | Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation |
| US20070015133A1 (en) * | 2005-07-13 | 2007-01-18 | Umc Utrecht Holding B.V. | Method for detecting and/or removing protein and/or peptide comprising a cross-beta structure from an aqueous solution comprising a protein |
| CA2615028A1 (en) * | 2005-07-13 | 2007-01-18 | Crossbeta Biosciences B.V. | Cross-.beta. structure binding compounds |
| US8114832B2 (en) * | 2005-07-13 | 2012-02-14 | Crossbeta Biosciences B.V. | Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition |
| EP1906995A2 (de) * | 2005-07-13 | 2008-04-09 | Crossbeta Biosciences B.V. | Adjuvation durch kreuzstruktur |
| US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| WO2008013859A2 (en) * | 2006-07-28 | 2008-01-31 | Adlyfe, Inc. | Peptide probes for diagnostics and therapeutics |
| US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
| PT2182983E (pt) | 2007-07-27 | 2014-09-01 | Janssen Alzheimer Immunotherap | Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| EP2058001A1 (de) * | 2007-11-08 | 2009-05-13 | Crossbeta Biosciences B.V. | Steigerung der Immunogenizität von Antigenen |
| EP2058000A1 (de) * | 2007-11-08 | 2009-05-13 | Crossbeta Biosciences B.V. | Zur Aktivierung von T-Zellen fähige immunogene Zusammensetzung |
| US20100021390A1 (en) * | 2008-03-17 | 2010-01-28 | The Research Foundation Of State University Of New York | Fluorescent Analogs Of The Islet Amyloid Polypeptide |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| RU2509155C1 (ru) * | 2012-10-25 | 2014-03-10 | Федеральное государственное бюджетное учреждение науки Институт биохимии им. А.Н. Баха Российской академии наук | Способ детекции белков в амилоидном состоянии и набор для детекции белков в амилоидном состоянии |
| GB201303507D0 (en) * | 2013-02-27 | 2013-04-10 | Hollfelder Florian | Assays |
| US9588129B2 (en) * | 2013-03-15 | 2017-03-07 | Amira Medical Technologies Inc. | Methods for analyzing blood to detect diseases associated with abnormal protein aggregation |
| CN104803993B (zh) * | 2015-03-01 | 2017-11-03 | 四川大学 | 一种具有Aβ亲和力的荧光化合物及其用途 |
| CN105651752B (zh) * | 2016-02-26 | 2019-04-12 | 国家纳米科学中心 | 淀粉样蛋白的检测方法 |
| CN105717182B (zh) * | 2016-03-10 | 2018-05-11 | 中南大学 | 一种用于同步检测淀粉样多肽单体和聚集体的生物传感器及其构建方法和应用 |
| US11536731B2 (en) | 2017-01-23 | 2022-12-27 | Rensselaer Polytechnic Institute | Systems and methods for binding amyloid fibrils using fluorescent protein |
| CN108489941B (zh) * | 2018-01-31 | 2021-07-27 | 吉林大学 | 溴酚蓝在作为检测牛胰岛素淀粉样纤维探针和作为牛胰岛素淀粉样纤维抑制剂方面的应用 |
| CN112912732A (zh) * | 2018-08-03 | 2021-06-04 | 香港大学 | 用于淀粉样蛋白原纤维、淀粉样蛋白斑块、rna和核仁的检测和成像的组合物和方法 |
| US12115141B2 (en) | 2018-11-14 | 2024-10-15 | University Of Kentucky Research Foundation | Diagnosis of diabetes by detecting aggregated amylin in erythrocytes |
| CN111504957B (zh) * | 2019-01-31 | 2021-12-03 | 吉林大学 | 一种维多利亚蓝b及其衍生物在制备异构化蛋白的探针或抑制剂中的应用 |
| KR102258048B1 (ko) * | 2019-05-30 | 2021-05-31 | 주식회사 캔티스 | 아밀로이드 베타 올리고머의 검출 방법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2013396A1 (en) * | 1989-04-05 | 1990-10-05 | Dennis J. Selkoe | Diagnostic method for alzheimer's disease: examination of non-neural tissue |
| US5276059A (en) | 1992-07-10 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition of diseases associated with amyloid formation |
| WO1997007402A1 (en) | 1995-08-17 | 1997-02-27 | The Ontario Cancer Institute | Protein fibril assembly assay |
| JPH0995444A (ja) * | 1995-10-02 | 1997-04-08 | Teijin Ltd | アミロイド蛋白凝集阻害剤 |
| EP1003539A4 (de) | 1997-08-14 | 2002-09-11 | Univ California | FLUORESZIERENDE AMYLOID A beta PEPTIDE UND DEREN VERWENDUNG |
| CA2323090C (en) * | 1998-03-13 | 2009-08-04 | University Of Washington | In vitro formation of congophilic maltese-cross amyloid plaques to identify anti-plaque therapeutics for the treatment of alzheimer's and prion diseases |
-
1999
- 1999-12-29 US US09/474,970 patent/US6399314B1/en not_active Expired - Fee Related
-
2000
- 2000-12-01 PT PT00980905T patent/PT1242822E/pt unknown
- 2000-12-01 WO PCT/US2000/032693 patent/WO2001050134A2/en not_active Ceased
- 2000-12-01 CN CNB008178658A patent/CN1211661C/zh not_active Expired - Fee Related
- 2000-12-01 ES ES00980905T patent/ES2309003T3/es not_active Expired - Lifetime
- 2000-12-01 PL PL00356813A patent/PL356813A1/xx not_active Application Discontinuation
- 2000-12-01 HK HK02108122.2A patent/HK1046550B/en not_active IP Right Cessation
- 2000-12-01 DK DK00980905T patent/DK1242822T3/da active
- 2000-12-01 AT AT00980905T patent/ATE399323T1/de not_active IP Right Cessation
- 2000-12-01 BR BR0016883-1A patent/BR0016883A/pt not_active Application Discontinuation
- 2000-12-01 AU AU18103/01A patent/AU774377B2/en not_active Ceased
- 2000-12-01 CA CA2395789A patent/CA2395789C/en not_active Expired - Fee Related
- 2000-12-01 MX MXPA02006362A patent/MXPA02006362A/es active IP Right Grant
- 2000-12-01 NZ NZ519612A patent/NZ519612A/en unknown
- 2000-12-01 JP JP2001550033A patent/JP2003519383A/ja active Pending
- 2000-12-01 DE DE60039310T patent/DE60039310D1/de not_active Expired - Lifetime
- 2000-12-01 IL IL15008000A patent/IL150080A0/xx active IP Right Grant
- 2000-12-01 EP EP00980905A patent/EP1242822B1/de not_active Expired - Lifetime
- 2000-12-01 KR KR1020027008505A patent/KR20020070470A/ko not_active Ceased
- 2000-12-01 EA EA200200722A patent/EA005582B1/ru not_active IP Right Cessation
-
2002
- 2002-06-06 IL IL150080A patent/IL150080A/en not_active IP Right Cessation
- 2002-06-28 NO NO20023163A patent/NO20023163L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1242822B1 (de) | 2008-06-25 |
| MXPA02006362A (es) | 2002-11-29 |
| IL150080A (en) | 2009-02-11 |
| ES2309003T3 (es) | 2008-12-16 |
| HK1046550B (en) | 2008-12-19 |
| PT1242822E (pt) | 2008-09-29 |
| CA2395789A1 (en) | 2001-07-12 |
| DE60039310D1 (de) | 2008-08-07 |
| CN1211661C (zh) | 2005-07-20 |
| NO20023163L (no) | 2002-08-27 |
| DK1242822T3 (da) | 2008-09-29 |
| AU1810301A (en) | 2001-07-16 |
| AU774377B2 (en) | 2004-06-24 |
| PL356813A1 (en) | 2004-07-12 |
| NZ519612A (en) | 2004-04-30 |
| CA2395789C (en) | 2010-03-30 |
| CN1415074A (zh) | 2003-04-30 |
| KR20020070470A (ko) | 2002-09-09 |
| NO20023163D0 (no) | 2002-06-28 |
| HK1046550A1 (en) | 2003-01-17 |
| WO2001050134A2 (en) | 2001-07-12 |
| ATE399323T1 (de) | 2008-07-15 |
| JP2003519383A (ja) | 2003-06-17 |
| EA005582B1 (ru) | 2005-04-28 |
| WO2001050134A3 (en) | 2002-06-27 |
| BR0016883A (pt) | 2002-10-01 |
| EP1242822A2 (de) | 2002-09-25 |
| US6399314B1 (en) | 2002-06-04 |
| EA200200722A1 (ru) | 2002-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL150080A0 (en) | Methods of detection of amyloidogenic proteins | |
| Solberg et al. | A five-year follow-up study of antioxidants, oxidative stress and polyunsaturated fatty acids in schizophrenia | |
| PH12020551371A1 (en) | Assays to detect neurodegeneration | |
| BG104275A (en) | Method and device for express analysis of tested parameters in biological samples | |
| AU2001295361A1 (en) | Method and device for determining the volume of a sample of a liquid | |
| Yin et al. | A two-input fluorescent logic gate for glutamate and zinc | |
| SG126066A1 (en) | Inspection method and system using multifrequency phase analysis | |
| DE59914830D1 (de) | Verfahren und testbesteck zur beurteilung der oxid messung ihrer antiradikalen aktivität | |
| Zinellu et al. | Highly sensitive simultaneous detection of cultured cellular thiols by laser induced fluorescence‐capillary electrophoresis | |
| TW200632320A (en) | Methods of in vitro analysis using time-domain nmr spectroscopy | |
| CN106544007B (zh) | 一种检测生物体系内次氯酸的荧光探针及其应用 | |
| Gołuński et al. | Modulation of acridine mutagen ICR191 intercalation to DNA by methylxanthines—analysis with mathematical models | |
| DE60229303D1 (de) | Bioäquivalenztest für eisenhaltige formulierungen | |
| Menge et al. | Comparing loss of individual fragile X proteins suggests strong links to cellular senescence and aging | |
| ATE487122T1 (de) | Vorrichtung zur bestimmung rheologischer eigenschaften | |
| DE60324820D1 (de) | Verfahren zum testen des oxidiertes-ldl-beta-2-glycoprotein-i-komplexes in vivo | |
| ATE466285T1 (de) | Diagnose von leberzirrhose mittels eines für menschliches protoonkogenes protein spezifischen antikörpers | |
| CN201229305Y (zh) | 食用菌荧光增白剂检测仪 | |
| RU2390778C2 (ru) | Способ оценки агрегационной способности эритроцитов | |
| CN110441457A (zh) | 一种检测尿液中同型半胱氨酸的方法 | |
| UA94920C2 (ru) | Способ быстрого выявления, выделения и подсчета апоптических клеток, который базируется на агглютинации | |
| Enriquez‐Algeciras et al. | Deimination level and peptidyl arginine deiminase 2 expression are elevated in astrocytes with increased incubation temperature | |
| Maruyama et al. | The effect of neuromelanin on the proteasome activity in human dopaminergic SH-SY5Y cells | |
| WO2005045395A3 (en) | Method of detecting bovine spongiform encephalopathy | |
| SU1746960A1 (ru) | Способ определени степени зрелости икры рыб |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |